Zoonotic Mycobacterium bovis-induced tuberculosis in humans. by Müller, Borna et al.
We aimed to estimate the global occurrence of zoonot-
ic tuberculosis (TB) caused by Mycobacterium bovis or M. 
caprae infections in humans by performing a multilingual, 
systematic review and analysis of relevant scientific litera-
ture of the last 2 decades. Although information from many 
parts of the world was not available, data from 61 countries 
suggested a low global disease incidence. In regions out-
side Africa included in this study, overall median proportions 
of zoonotic TB of <1.4% in connection with overall TB in-
cidence rates <71/100,000 population/year suggested low 
incidence rates. For countries of Africa included in the study, 
we multiplied the observed median proportion of zoonotic 
TB cases of 2.8% with the continental average overall TB in-
cidence rate of 264/100,000 population/year, which resulted 
in a crude estimate of 7 zoonotic TB cases/100,000 popula-
tion/year. These generally low incidence rates notwithstand-
ing, available data indicated substantial consequences of 
this disease for some population groups and settings.
Tuberculosis (TB) is among the most devastating hu-man infectious diseases worldwide. An estimated 
8.8 million new cases, a global average incidence rate of 
128/100,000 population/year, and 1.5 million deaths were 
attributed to TB in 2010 (1). Human TB is caused prin-
cipally by M. tuberculosis. The main causative agents of 
bovine TB are M. bovis and, to a lesser extent, M. cap-
rae; however, zoonotic transmission of these pathogens is 
well described and occurs primarily through close contact 
with infected cattle or consumption of contaminated animal 
products such as unpasteurized milk (2,3). TB cases caused 
by transmission of other mycobacteria from other animal 
reservoirs (e.g., wildlife) have been anecdotally reported 
(4,5). Globally, most cases of zoonotic TB are caused by 
M. bovis, and cattle are the major reservoir (2,3). There-
fore, for the purpose of this study and the remainder of this 
report, we refer to zoonotic TB as TB in humans caused by 
M. bovis or M. caprae.
There is evidence to suggest that zoonotic TB 
accounted for a significant proportion of the TB cases in 
the Western world before the introduction of regular milk 
pasteurization programs (6,7). Currently, in high-income 
countries, bovine TB is well controlled or eliminated in 
most areas, and cases of zoonotic TB are rarely seen (6,7). 
However, reservoirs of TB in wildlife populations have 
been linked to the persistence or increase of the incidence 
of bovine TB in some countries, most notably the United 
Kingdom (UK) (6). The absence of zoonotic TB despite 
an upsurge in the incidence of bovine TB in the United 
Kingdom sparked a controversy over the large financial 
expenditures for disease control in cattle (6).
The situation may be fundamentally different in other 
regions. For example, in most countries in Africa, bovine TB 
is prevalent, but effective disease control, including regular 
milk pasteurization and slaughterhouse meat inspection, is 
largely absent (2,3). This situation is exacerbated by the 
presence of multiple additional risk factors such as human 
behavior and the high prevalence of HIV infections (2,3,7). 
Although HIV/AIDS is thought to facilitate transmission 
and progression to active disease of any form of TB, some 
studies showed a significantly increased proportion of 
M. bovis infections among HIV–co-infected TB patients 
compared with HIV-negative TB patients (8–12).
No assessment of the global consequences of zoonotic 
TB has yet been done. This may have been partially 
caused by the difficulty of differentiating TB caused by 
M. tuberculosis or M. bovis, which requires mycobacterial 
culture and the subsequent use of biochemical or molecular 
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(e.g., genotyping) diagnostic methods. Therefore, in low-
income countries, facilities to identify the causative agent 
of TB are largely absent (2,3,7). A previous comprehensive 
review on zoonotic TB was published 15 years ago with 
inferences based primarily on the presence of risk factors 
rather than the occurrence of actual cases (2). Since then, 
several studies of zoonotic TB in different parts of the world 
have been published, enabling a more detailed evaluation 
of the current importance of the disease. The current study 
was mandated by the World Health Organization (WHO) 
Foodborne Disease Burden Epidemiology Reference 
Group with the aim to determine, on the basis of previously 
published literature, the global occurrence of zoonotic 
TB and its contribution to the overall TB prevalence in 
affected settings.
Materials and Methods
A systematic multilingual literature search was 
performed according to international guidelines with 
certain modifications (www.cochrane-handbook.org/).
Potentially relevant reports on putative zoonotic TB caused 
by M. bovis or M. caprae were identified by a search of 
32 bibliographic databases by using a highly sensitive 
search syntax. All publications/reports documented in 
the various databases and published until March 2010 
were considered (Table 1, online Technical Appendix 1, 
wwwnc.cdc.gov/EID/article/19/6/12-0543-Techapp1.pdf, 
and online Technical Appendix 2, wwwnc.cdc.gov/EID/
article/19/6/12-0543-Techapp2.xlsx). Reference Manager 
v11.0.1 bibliographic software was used to store and 
remove duplicated reports, leaving 12,176 records (Figure 
1). Titles and abstracts of these reports were screened to 
remove studies unlikely to contain pertinent information. 
Altogether, 1,203 potentially relevant reports were 
identified (online Technical Appendix 1, 2) of which 447 
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Figure 1. Selection procedure for reports included in this analysis. 
A list of all identified 1,203 potentially relevant reports and the core 
dataset is available as supplemental material (online Technical 
Appendix 2, wwwnc.cdc.gov/EID/article/ 19/6/12-0543-Techapp2.
xlsx). TB, tuberculosis; M. bovis, Mycobacterium bovis.
Table 1. Number of countries within World Health Organization regions for which the respective data on zoonotic Mycobacterium 
bovis–induced TB in humans was obtained* 
Variables 
No. (%) of countries by WHO region 
Africa Americas Europe 
Eastern 
Mediterranean 
Western 
Pacific 
Total number of countries in WHO region† 46 (100.0) 35 (100.0) 53 (100.0) 22 (100.0) 27 (100.0) 
Any data for countries of WHO region indicated‡ 13 (28.3) 12 (34.3) 31 (58.5) 2 (9.1) 3 (11.1) 
Nationwide data 0 10 (83.3) 30 (96.8) 0 2 (66.7) 
Subnational data 13 (100.0) 5 (41.7) 11 (35.5) 2 (100.0) 2 (66.7) 
Surveillance data 6 (46.2) 5 (41.7) 31 (100.0) 1 (50.0) 3 (100.0) 
Convenience sample/unknown sampling strategy 10 (76.9) 11 (91.7) 6 (19.4) 1 (50.0) 2 (66.7) 
Nationwide surveillance data 0 2 (16.7) 30 (96.8) 0 2 (66.7) 
Molecular-based detection of M. bovis 10 (76.9) 7 (58.3) 9 (29.0) 2 (100.0) 3 (100.0) 
Biochemical detection of M. bovis 6 (46.2) 3 (25.0) 4 (12.9) 0 1 (33.3) 
Other detection method 1 (7.7) 3 (25.0) 3 (9.7) 0 1 (33.3) 
Unknown detection method 0 10 (83.3) 30 (96.8) 0 2 (66.7) 
Data on average yearly prevalence 9 (69.2) 6 (50.0) 5 (16.1) 0 2 (66.7) 
Data on average yearly prevalence per 100,000 
population 
0 0 0 0 0 
Data on average yearly incidence 6 (46.2) 10 (83.3) 31 (100.0) 1 (50.0) 3 (100.0) 
Data on average yearly incidence per 100,000 
population 
2 (15.4) 7 (58.3) 30 (96.8) 1 (50.0) 2 (66.7) 
Data on average yearly mortality 0 1 (8.3) 2 (6.5) 0 0 
Data on average yearly mortality per 100,000 
population 
0 1 (8.3) 0 0 0 
Data on proportion among all TB cases 13 (100.0) 12 (100.0) 30 (96.8) 2 (100.0) 3 (100.0) 
Data on proportion among all TB deaths 0 1 (8.3) 0 0 0 
Data on proportion of deaths among all TB cases 0 1 (8.3) 2 (6.5) 0 0 
*TB, tuberculosis; WHO, World Health Organization; Freq, Number of countries represented by records reporting on the indicated variable; %, proportions 
related to the total number of countries in a given WHO region for which data were available (unless otherwise indicated). 
†No data were obtained for Southeast Asia. 
‡Proportions relate to the total number of countries in the respective WHO region. 
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(37%) were available online and assessed for eligibility 
(Figure 1). 
Eligible records (written in English, French, German, 
Spanish, or Portuguese) reported data for at least 50 persons 
tested on the frequency (prevalence, incidence) or death 
rate of putative zoonotic TB and contained data from no 
earlier than 1990. In connection with other ongoing studies, 
records reporting information on disease sequelae and 
transmission routes were also included. For 100 randomly 
selected reports of the 1,203 potentially relevant reports, 
availability and eligibility was assessed independently by 
3 operators. Differently appraised records were reassessed, 
and the screening procedure was harmonized accordingly. 
The remaining records were randomly assigned to 1 of the 
3 individual operators for further assessment; 140 records 
were considered eligible and subjected to data extraction. 
The data were stratified by multiple variables, if possible 
(e.g., country or province, HIV status). If any of the reports 
included referred to relevant external data or eligible reports 
that were not identified during the earlier steps of our 
literature search, the respective data were also included in 
this analysis. For 15 randomly selected reports of the 140 
eligible records and additional data cited by or referring to 
these records, data extraction was performed independently 
by the 3 operators. Differently extracted data was reassessed 
and the extraction procedure was harmonized accordingly. 
The remaining records were randomly assigned to one of the 
3 operators for data extraction. Of 140 eligible records, 91 
reported or referred to data on disease frequency or mortality 
rates of putative zoonotic TB (online Technical Appendix 1 
Figure 2). If accessible, additional population estimates and 
official TB notifications were included in the database. This 
core dataset was used to analyze, by geographic region and 
country, the global occurrence of zoonotic TB in humans 
and its contribution to the overall TB prevalence in affected 
settings. A subset of data stratified by HIV status was used 
to assess a potential association between TB caused by M. 
bovis and HIV co-infection. For each of these analyses, 
duplicated data, present in >1 report was removed from the 
core dataset (Figure 1). Statistical analyses were performed 
in IC Stata 10.0 (StataCorp LP, College Station, TX, USA).
Results
Data Availability
Data obtained from eligible reports covered 5 of 
6 WHO regions (Table 1; online Technical Appendix 
1 Table 1), namely Africa, the Americas, Europe, the 
Eastern Mediterranean and the Western Pacific. No data 
were obtained for any country in Southeast Asia. With the 
exception of Europe, data were acquired for only a few 
countries of the regions represented in this analysis (online 
Technical Appendix 1 Table 1). Notably, for the Eastern 
Mediterranean and the Western Pacific regions, respectively, 
data from only 2 and 3 countries were obtained. The 
considerable lack of data precluded a credible estimation of 
the global prevalence and incidence of zoonotic TB.
Zoonotic TB in Africa
Among all studies included from Africa, a median of 
2.8% (range 0%–37.7%) of all TB cases in humans were 
caused by M. bovis (Figure 2). In 10 of the 13 countries 
in Africa included in this study, median proportions of 
TB caused by M. bovis were below 3.5% and in 5 of these 
countries no cases were detected (Table 2; Figure 3). In 
contrast, for Ethiopia, Nigeria and Tanzania, respectively, 
the median proportion of TB cases caused by M. bovis was 
17.0% (range: 16.7%–31.4%) (13–15), 15.4% (1 study 
available) (16) and 26.1% (range 10.8%–37.7%) (17–19). 
Percentages of ≈30% were reported in 4 regionally based 
studies in Tanzania and Ethiopia (Figure 3, Table 2) 
(13,17). However, many of these studies showed a low 
sample size, resulting in a high statistical error (Table 
2). The lack of large-scale, population-based data did not 
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Figure 2. Proportion of zoonotic tuberculosis (TB) among all TB 
cases (A) and estimated overall TB incidence (B) stratified by World 
Health Organization (WHO) region. Overall TB incidence rates 
estimated for 2010 by WHO regions covered all countries of the 
respective regions. The lower end of each gray box represents the 
25th percentile, and the upper end represents the 75th percentile; 
horizontal lines inside the gray boxes represent the median. 
Whiskers indicate upper and lower adjacent values; circles indicate 
outliers. Numbers were obtained from WHO (1).
SYNOPSIS
allow for an identification of specific risk groups associated 
with M. bovis infections.
Zoonotic TB in the Americas
A median of 0.3% (range 0%–33.9%) of M. bovis 
infections among human TB cases was found for all 
reports included. For most countries, M. bovis accounted 
for a negligible percentage of the TB cases (Figure 2). 
Conversely, high proportions were reported for specific 
areas of Mexico and the United States (Figure 4). For 
Mexico, the median percentage of M. bovis cases was 
7.6% (range 0%–31.6%); proportions >10% were detected 
in 3 independent studies (20–22). However, overall 
TB incidence in Mexico is relatively low, with a rate of 
16/100,000 population/year (1). In the United States, TB 
caused by M. bovis is strongly linked to persons in Hispanic 
communities, mostly with origins in Mexico (Table 3). A 
study including data from 41 states of the United States 
suggested that ≈90% of all TB cases caused by M. bovis 
affect persons of Hispanic ethnicity (8). This association 
is attributed to the consumption of unpasteurized, 
contaminated cheese produced in Mexico. Moreover, 
when multivariate logistic regression analyses was used, 
several studies in the United States showed an independent 
association of TB caused by M. bovis with TB cases in 
children, HIV coinfection and extrapulmonary disease (8–
12). Surveys in San Diego County, California indicated a 
steady increase in the incidence of TB caused by M. bovis 
and a decrease in TB incidence caused by M. tuberculosis 
infection (9,12). In this setting, the odds for TB patients 
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Table 2. Overview of selected reports from Africa on zoonotic Mycobacterium bovis–induced TB in humans* 
ID Country Setting Sampling Detection Years 
M. 
bovis† TB‡ %§ 95% CI Location 
1131 Tanzania NA Conv. Mol. NA 20 53 37.7 24.8–52.1 EPTB 
1131 Tanzania Arusha region Conv. Mol. 1994 4 11 36.4 10.9–69.2 EPTB 
1074 Ethiopia Butajira health center, 
southeastern Ethiopia 
System. Mol. 2000/2001 11 35 31.4 16.9–49.3 EPTB 
1074 Ethiopia NA Conv. Biochem. NA 14 48 29.2 17.0–44.1 PTB 
15 Ethiopia Felegehiwot hospital Conv. Biochem. 2007/2008 8 47 17.0 7.6–30.8 Both 
65 Ethiopia NA Conv. Biochem. NA 7 42 16.7 7.0–31.4 Both 
1074 Ethiopia Fitche Hospital TB clinic Conv. Biochem. 2004/2005 7 42 16.7 7.0–31.4 Both 
294 Tanzania Arusha region and 
Southern Highlands 
Surv. Biochem. 1993–1996 7 44 15.9 6.6–30.1 Both 
73 Nigeria Jos Conv. Biochem. NA 10 65 15.4 7.6–26.5 PTB 
68 Uganda Karamojo region Conv. Mol. NA 3 24 12.5 2.7–32.4 EPTB 
159 Tanzania Three districts in Arusha 
region 
Surv. Biochem. 1999–2001 7 65 10.8 4.4–20.9 EPTB 
459 Malawi Blantyre, Queen Elizabeth 
Central Hospital 
Conv. Biochem. NA 1 30 3.3 0.1–17.2 PTB 
62 Ghana Korle-Bu Teaching 
Hospital 
Conv. Biochem. 2003 2 64 3.1 0.4–10.8 PTB 
464 Madagascar Institut d'Hygiène Sociale, 
Antananarivo 
Conv. Mol. 1994 3 126 2.4 0.5–6.8 PTB 
340 Madagascar Antananarivo Surv. Other 1994/1995 2 156 1.3 0.2–4.6 EPTB 
292 Madagascar Antananarivo, Antsirabe, 
Fianarantsoa, and 
Mahajanga 
Rand. Mol. 1994/1995 4 316 1.3 0.3–3.2 PTB 
243 Uganda Kampala Conv. Biochem. 1995–1997 1 234 0.4 0.0–2.4 PTB 
52 Uganda Kampala, Rubaga division Surv. Mol. 2006 1 386 0.3 0.0–1.4 PTB 
222 Cameroon Ouest Province Surv. Mol. 1997/1998 1 455 0.2 0.0–1.2 PTB 
80 Burkina Faso Health centers in 
Ouagadougou and Bobo 
Dioulasso 
Conv. Mol. 2001 0 120 0.0 0.0–3.0¶ PTB 
12 Burundi Bujumbara, Bubanza 
Hospital 
Conv. Mol. 1987–1994 0 117 0.0 0.0–3.1¶ Both 
165 Chad Chari-Baguirmi Conv. Mol. 2002 0 10 0.0 0.0–30.8¶ Both 
12 Côte d'Ivoire TB and rural health 
centers in Côte d’Ivoire 
Cluster Mol. 1994–1996 0 320 0.0 0.0–1.1¶ PTB 
464 Madagascar Antananarivo prison Conv. Mol. 1994 0 36 0.0 0.0–9.7¶ PTB 
12 Sierra Leone Western Area and 
Kenema districts 
Surv. Mol. 2003/2004 0 97 0.0 0.0–3.7¶ PTB 
32 Uganda Mbarara district Rand. Mol. 2004/2005 0 70 0.0 0.0–5.1¶ Both 
*TB, tuberculosis; ID, record identification number (online Technical Appendix 2, wwwnc.cdc.gov/EID/article/19/6/12-0543-Techapp2.xlsx); NA, not 
available; Conv., convenience sample/not specified; Mol., molecular-based detection method; EPTB, extrapulmonary TB; System, systematic sampling; 
Biochem, biochemical detection method; PTB, pulmonary TB; Surv.,surveillance data; Rand., random sampling; Cluster, cluster sampling. 
†Number of putative zoonotic cases of Mycobacterium bovis. 
‡Total number of bacteriologically confirmed and characterized TB cases. 
§%, proportion of zoonotic TB among all TB cases. 
¶One-sided 97.5% CIs are indicated. 
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infected with M. bovis to die during treatment was >2 
times as high as for patients infected with M. tuberculosis 
(9,10,12). In San Diego County, during 1994–2003 and 
2001–2005, respectively, M. bovis accounted for 25 and 
19 deaths, corresponding to 27% and 17% of all TB deaths 
and a mortality rate of ≈0.1/100,000 population/year (9,10). 
The reasons for increased deaths among patients infected 
with zoonotic TB compared with those infected with M. 
tuberculosis remained unidentified, although health care 
inequality or treatment differences were stated as possible 
explanations (9). However, overall incidence rates of 
zoonotic TB in the United States are low, at a median of 
0.7/100,000 population/year. Although zoonotic TB causes 
minor consequences of disease in the Americas, available 
data corroborate the finding that M. bovis infections can be 
a substantial cause of deaths from TB among humans in 
certain population groups and settings.
Zoonotic TB in Europe
Studies from Austria, Germany, Greece, and Spain 
included in this analysis identified M. caprae as a causative 
agent of zoonotic TB in addition to M. bovis (23–26). Our 
analysis revealed a median proportion of 0.4% (range 
0%–21.1%) of M. bovis or M. caprae infections among 
all bacteriologically confirmed TB cases reported. Median 
proportions for individual countries never reached rates 
>2.3%, although higher percentages were found for specific 
populations and settings (Figure 5). Three of 5 studies 
reporting proportions >10% were conducted in settings 
with very low incidences of human TB (<20 cases/year on 
a countrywide level) (27). In another hospital-based study 
in Germany, 4 M. bovis cases were identified among 19 TB 
cases with molecular speciation results, 2 of which probably 
represented disease caused by the treatment of urothelial 
carcinoma with M. bovis BCG (28). A study in Spain 
characterized the transmission of a multidrug-resistant 
strain of M. bovis as the cause of 2 nosocomial TB outbreaks 
that accounted for 12.2% of multidrug-resistant TB isolates 
(29). However, these cases did not represent cases of 
zoonotic TB, because transmission occurred from humans 
to humans. Reported incidence rates for TB caused by M. 
bovis or M. caprae for all studies included from European 
countries were <1/100,000 population/year if TB cases 
caused by multidrug-resistant strains of M. bovis in Spain 
were excluded (online Technical Appendix 2). Moreover, 
available data suggested decreasing trends in the number of 
zoonotic TB cases over time (online Technical Appendix 2).
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Figure 3. Proportion of zoonotic tuberculosis (TB) among all TB 
cases stratified by country: Africa. X-axis values are proportion of 
zoonotic TB cases among all TB cases. Each circle represents a 
study with the circle diameter being proportional to the log10 of the 
number of isolates tested. A gray rhombus indicates that the number 
of samples tested was not reported or could not be inferred from 
the data available. The median proportion of all studies for a given 
country is indicated by X. Numbers on the right side of the figures 
indicate the number of studies included for any given country.
Figure 4. Proportion of zoonotic tuberculosis (TB) among all TB cases 
stratified by country: Americas. X-axis values are are proportion of 
zoonotic TB cases among all TB cases. Each circle represents a 
study with the circle diameter being proportional to the log10 of the 
number of isolates tested. A gray rhombus indicates that the number 
of samples tested was not reported or could not be inferred from 
the data available. The median proportion of all studies for a given 
country is indicated by X. Numbers on the right side of the figures 
indicate the number of studies included for any given country.
SYNOPSIS
Zoonotic TB in the Eastern Mediterranean
One study from the Suez Canal region of Egypt reported 
a rate of 2.2% (95% CI 0.1%–11.8%) for pulmonary TB 
cases caused by M. bovis (30). A second nationwide study 
in Djibouti detected 0.6% (95% CI 0.0%–3.5%) of the TB 
lymphadenitis cases for which samples were tested to be 
caused by M. bovis (31). No other studies were obtained 
for the WHO region of the Eastern Mediterranean. The 
proportion of zoonotic TB among all TB cases in the 
eastern Mediterranean is shown in Figure 6.
Zoonotic TB in the Western Pacific
Data obtained from the Western Pacific region was 
from Australia, New Zealand, and parts of China only. 
For these settings, respectively, median proportions of M. 
bovis infections of 0.2% (range 0.1%–0.7%), 2.7% (range 
2.4%–5%) and 0.2% (range 0%–0.5%) among all TB cases 
analyzed were observed, indicating that zoonotic TB had 
minor importance Median incidence rates were 0.03 (range 
0.00–0.60) and 0.16 (range 0.11–0.27)/100,000 population/
year for Australia and New Zealand, respectively. The 
infrequent occurrence of zoonotic TB in these settings 
notwithstanding, New Zealand showed a generally higher 
proportion and incidence rate for TB caused by M. bovis 
than did Australia (Figure 6). While a steadily increasing 
proportion of TB caused by M. bovis was observed in 
New Zealand, trends were decreasing in Australia (online 
Technical Appendix 2).
Influence of HIV Co-infection
Seven surveys covering Ethiopia, Tanzania, Argentina, 
Mexico, and different parts of the United States provided 
data for analysis of a potential association between HIV co-
infection and zoonotic TB (Table 4) (8–10,13,18,20,32). 
Among these studies, only studies from the United States 
showed a significantly higher proportion of TB caused by 
M. bovis for HIV co-infected TB patients (Table 4). For 
studies from the USA, the relative risk for an infection with 
M. bovis among TB patients was 2.6–8.3 times higher in 
HIV–co-infected patients than in HIV-negative patients. 
No significant association between M. bovis infection and 
HIV status was identified in surveys in Africa or other 
countries of the Americas (Table 4).
Discussion
Naturally, the occurrence of zoonotic TB is greatly 
dependent on the presence of TB in cattle. Information 
on the global distribution and prevalence of bovine TB 
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Table 3. Selected reports from the United States on zoonotic Mycobacterium bovis-induced TB in humans* 
ID Setting Study period Ethnicity or place of birth No. cases† No. tested‡ %§ 
46 41 states in the United States 1995–2005 Native American, non-Hispanic 0 243 0.0 
Asian, non-Hispanic 5 2,938 0.2 
Black, non-Hispanic 6 3,447 0.2 
Hispanic 147 2,724 5.4 
White, non-Hispanic 7 2,449 0.3 
Mexico-born 102 1,399 7.3 
Non-US/Mexico-born 15 4,907 0.3 
US-born 47 5,531 0.8 
48 San Diego County, California 2001–2005 Hispanic 128 657 19.5 
White 3 154 1.9 
Asian 1 421 0.2 
Black 0 86 0.0 
Other 0 6 0.0 
Mexico-born 79 461 17.1 
The Philippines 0 248 0.0 
Non-US/Mexico/The Philippines-born 0 260 0.0 
US-born 53 355 14.9 
164 San Diego County, California 1994–2003 Hispanic 156 531 29.4 
Non-Hispanic 11 564 2.0 
Mexico-born 93 374 24.9 
Non-US/Mexico-born 3 416 0.7 
US-born 71 305 23.3 
155 New York, New York, USA 2001–2004 Mexico-born 20 155 12.9 
Non–Mexico-born 15 2925 0.5 
233 San Diego County, California 1994–2000 Mexico-born 70 553 12.7 
The Philippines 1 423 0.2 
Non-US/Mexico/The Philippines–-born 2 403 0.5 
US-born 56 552 10.1 
*TB. tuberculosis; ID, record identification number (online Technical Appendix 2, wwwnc.cdc.gov/EID/article/19/6/12-0543-Techapp2.xlsx).  
†N number of zoonotic TB cases identified. 
‡Number of TB case-patients tested for the presence of M. bovis infection.  
§ Proportion of zoonotic TB among all TB cases. 
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is scarce, but available data suggest that TB in cattle 
is prevalent in virtually all major livestock-producing 
countries of the developing world and Africa, specifically 
(2,3,7). Disease control in cattle is largely absent in 
these regions. Consequently, the majority of the human 
population is at risk for exposure to bovine TB; and 
globally, the occurrence of zoonotic TB likely mirrors TB 
prevalence in cattle.
Our systematic literature search on the occurrence 
of zoonotic TB provided no data for the WHO region of 
Southeast Asia, including major cattle producing middle- 
and low-income countries (e.g., India, Bangladesh, 
Pakistan, Myanmar, Indonesia) (online Technical 
Appendix 1) (33). Moreover, except for Europe, data were 
acquired for few countries of the regions represented in 
this analysis (Table 1) with some, in terms of livestock 
production, particularly relevant countries missing (e.g., 
Canada, Kenya, Russia, South Africa, Sudan, and Turkey) 
(33). Nationwide surveillance data were almost exclusively 
available for high-income countries that have programs in 
place for bovine TB control and regular milk pasteurization 
(Table 1). Although ample data were obtained for many 
low-risk, high-income countries, the lack of nationwide 
surveys in potential high-risk settings precluded a credible 
estimation of the global occurrence of zoonotic TB.
Recorded incidence rates for zoonotic TB in Europe, the 
United States, Australia, and New Zealand were consistently 
below 1/100,000 population/year (online Technical 
Appendix 2). Incidence rates were unavailable for other 
countries. However, a crude estimate could be obtained by 
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Figure 5. Proportion of zoonotic tuberculosis (TB) among all TB 
cases stratified by country: Europe. X-axis values are are proportion 
of zoonotic TB cases among all TB cases. Each circle represents a 
study with the circle diameter being proportional to the log10 of the 
number of isolates tested. A gray rhombus indicates that the number 
of samples tested was not reported or could not be inferred from 
the data available. The median proportion of all studies for a given 
country is indicated by X. Numbers on the right side of the figures 
indicate the number of studies included for any given country.
Figure 6. Proportion of zoonotic tuberculosis (TB) among all TB 
cases stratified by country: A) Eastern Mediterranean; B) Western 
Pacific. X-axis values are are proportion of zoonotic TB cases 
among all TB cases. Each circle represents a study with the circle 
diameter being proportional to the log10 of the number of isolates 
tested. A gray rhombus indicates that the number of samples tested 
was not reported or could not be inferred from the data available. 
The median proportion of all studies for a given country is indicated 
by X. Numbers on the right side of the figures indicate the number 
of studies included for any given country.
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multiplying the observed country-specific median proportion 
of zoonotic TB by the respective overall TB incidence rates. 
This suggested incidence rates of zoonotic TB of ≈1/100,000 
population/year or lower for all countries outside Africa 
included in this survey, except for the Republic of Djibouti 
(WHO Eastern Mediterranean Region) which reported ≈4 
zoonotic TB cases/100,000 population/year.
Africa is assumed to bear the highest consequences 
of zoonotic TB worldwide because of the frequent and 
concurrent presence of multiple risk factors (2,3,7). This 
is supported by the highest reported median proportions of 
TB caused by M. bovis in connection with the worldwide 
highest overall TB incidence rates (Figure 2). Given an 
observed median proportion of zoonotic TB of 2.8% 
and the continental average overall incidence of TB of 
264/100,000 population/year (Figure 2), an incidence rate 
of 7 zoonotic TB cases/100,000 population/year could be 
estimated (≈20 times lower than the global overall TB 
incidence rate) (1). Presumably, this is an overestimate 
as high-risk livestock producing countries of Africa 
(e.g., Ethiopia, Madagascar, Nigeria, and Tanzania) were 
overrepresented in this analysis (33) and because studies 
reporting the presence of zoonotic TB can be expected 
to be overrepresented among the surveys included (see 
limitations of the study below). Together, this suggests a 
low incidence of zoonotic TB in Africa.
Individual studies from various regions reported high 
proportions of zoonotic TB for specific population groups 
and settings (Figures 3–7). For example, in the Hispanic 
community in the United States, zoonotic TB appeared to 
be a considerable proportion of all TB cases (Table 3) and 
was associated with the consumption of unpasteurized 
cheese from Mexico (8–12). The highest median 
proportions for TB caused by M. bovis were observed 
in countries in Africa: Ethiopia, Nigeria, and Tanzania 
(Figure 3). However, the specific populations affected 
and risk factors of zoonotic TB in these settings remain 
largely elusive. The highest proportions of zoonotic TB 
in Africa were reported in studies investigating cases of 
extra-pulmonary TB (Table 2). For example, of a total of 
26 studies, 11 studies reported proportions of zoonotic TB 
>10%; 9 of those included cases of extrapulmonary TB; 
of the 15 studies reporting a proportion of zoonotic TB 
<3.3%, only 4 included extrapulmonary TB cases (Table 
2). This may mirror a widely stated association of zoonotic 
TB with extra-pulmonary disease, perhaps reflecting the 
consumption of contaminated animal products as one 
of the main drivers of zoontic TB (2,3,7). It has been 
postulated that pastoralist and rural communities would 
be at greatest risk for zoonotic TB (2,3,7), but the lack 
of data for these population groups prevents confirmation 
of this assumption. Collected individual studies reporting 
high proportions of TB caused by M. bovis suggest pockets 
of zoonotic transmission of TB for specific population 
groups and settings.
Outside Africa, large proportions of M. bovis infections 
among TB case-patients have been found mostly in low-
TB incidence settings such as Mexico. In Cyprus, Iceland, 
and Malta, proportions of TB caused by M. bovis of >10% 
were observed (Figure 5); however, these countries, 
nationwide, reported <20 human TB cases in the respective 
years. Similarly, a study in San Diego County, California, 
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Table 4. Available data on zoonotic Mycobacterium bovis–induced TB in humans, stratified by HIV-positive and -negative persons* 
ID Region Country HIV status No. cases No. tested % 95% CI RR 
1074 Africa Ethiopia + 4 10 40.0 12.2–73.8 1.43 
1074 Africa Ethiopia – 7 25 28.0 12.1–49.4 NA 
1147 Africa Tanzania + 2 29 6.9 0.8–22.8 0.50 
1147 Africa Tanzania – 5 36 13.9 4.7–29.5 NA 
NA Africa Total + 6 39 15.4 5.9–30.5 0.78 
NA Africa Total – 12 61 19.7 10.6–31.8 NA 
57 Americas Argentina + 2 240 0.8 0.1–3.0 0.88 
57 Americas Argentina – 95 10,000 1.0 0.8–1.2 NA 
57 Americas Argentina + 8 1,391 0.6 0.2–1.1 2.66 
57 Americas Argentina – 12 5,551 0.2 0.1–0.4 NA 
39 Americas Mexico + 11 80 13.8 7.1–23.3 1.90 
39 Americas Mexico – 6 83 7.2 2.7–15.1 NA 
46 Americas USA + 21 891 2.4 1.5–3.6* 2.59 
46 Americas USA – 59 6,472 0.9 0.7–1.2* NA 
48 Americas USA + 33 140 23.6 16.8–31.5* 3.24 
48 Americas USA – 48 659 7.3 5.4–9.5* NA 
164 Americas USA + 39 64 60.9 47.9–72.9* 8.32 
164 Americas USA – 35 478 7.3 5.2–10.0* NA 
NA Americas Total + 114 2806 4.1 3.4–4.9* 3.70 
NA Americas Total – 255 23,243 1.1 1.0–1.2* N/A 
*TB, tuberculosis; ID, Record identification number (online Technical Appendix 2, wwwnc.cdc.gov/EID/article/19/6/12-0543-Techapp2.xlsx); Cases, 
number of zoonotic tuberculosis (TB) cases identified; Tested, number of TB cases tested for the presence of M. bovis infection; %, proportion of zoonotic 
TB among all TB cases; RR, relative risk ratio; NA, not available. 
Significantly higher proportion of M. bovis infection among TB patients with HIV coinfection. 
 
Zoonotic M. bovis TB in Humans
USA, showed an overall decreasing incidence of human 
TB while the incidence of zoonotic TB and therefore 
also the relative proportion of zoonotic TB has steadily 
increased (9,12). This suggests that commonly applied 
control efforts targeting M. tuberculosis transmission 
have little effect on the occurrence of zoonotic TB and 
probably reflects the distinct drivers of M. tuberculosis 
and zoonotic TB infection (e.g., aerosol transmission vs. 
foodborne infection) (2,3). Similarly, differences in the 
epidemiology of zoonotic TB are likely to exist between 
different regions. This could be mirrored by the association 
of zoonotic TB with HIV in the United States, but not in 
other areas included in this analysis (Table 4). Ascertaining 
the factors contributing to an association between HIV and 
zoonotic TB in some regions will require more in-depth 
research, thus eliminating potential confounders such as 
socioeconomic status, education level, national origin, and 
other factors.
The current study is affected by several biases. The 
sensitivity of this systematic literature review was affected 
by the selection of eligible reports and data extraction by 
a single operator. Also, only reports available online and 
written in English, French, German, Spanish, or Portuguese 
were included. Selected reports are biased toward surveys 
which identified or aimed to identify TB cases caused by 
M. bovis, possibly resulting in an overestimation of the 
proportion of zoonotic TB cases. Data from low-income 
countries included in this study were rarely comparable and 
not representative of the respective nationwide populations. 
Nonetheless, it seems unlikely that our conclusions 
were fundamentally affected by these biases. Lastly, 
our results are influenced by the technical constraints of 
the studies included. Specifically, biochemical methods 
may be relatively unreliable for the identification of M. 
bovis or M. caprae strains and routine culture methods 
for M. tuberculosis are suboptimal to detect strains of M. 
bovis (2,3). Thus, TB cases caused by M. bovis may be 
systematically underreported.
Reports published after the completion of this 
systematic review revealed information from countries 
not covered by this study. A study from Bangladesh 
analyzed isolates from 350 TB patients but did not 
identify any infections by M. bovis (34). In a study from 
Bamako, Mali, 0.8% of TB cases analyzed were caused 
by M. bovis (35). In Turkey and the West Bank, Palestine, 
respectively, 5.3% and 6.5% of clinical TB cases analyzed 
were caused by M. bovis (36,37); however, zoonotic TB 
can be considered rare in these areas, given the low overall 
incidence rates of TB of 28 and 0.7/100,000 population/
year (1,38). Together, available data suggest a minor 
global importance of zoonotic TB. However, pockets 
of more frequent zoonotic transmission of TB seem to 
be present in certain population groups. More research 
is needed to identify the main transmission drivers in 
these areas.
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